← Patent-cliff monitor small molecule IBRANCE PALBOCICLIB
Loss of exclusivity August 2034 latest FDA-listed patent expiry
Company Pfizer → See this company's full patent-cliff portfolio Drug detail Brand name IBRANCE Active ingredient PALBOCICLIB Strength 100MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval February 2015 Marketing status RX
Listed patents Patent Expires Type 10723730*PED August 2034 — 10723730 February 2034 substance, product RE47739*PED September 2027 — RE47739 March 2027 substance, product
Regulatory exclusivity Code Expires I-995 June 2029 PED March 2029 M-14 September 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.